Key Stats
52-Week Range
Choose a result to open the company. Use arrow keys to choose a result and Enter to confirm.
Choose a result to open the company. Use arrow keys to choose a result and Enter to confirm.
#3167 ๐บ๐ธ US
NASDAQยทOABI
$5.0300
โฌ4.59
-0.98% (24h)
Market Cap
$733.68M
โฌ668.82M
Volume (24h)
1.75M shrsยท $8.79M
โฌ8.02M
Last Close (7D)
$5.03
โฌ4.59
Prices in USD. No currency conversion.
52-Week Range
Q3 FY2026ended 2026-09-30 ยท filed 2026-10-30
$3.99M
$-15.73M
$-16.37M
-$0.12
$22.88M
$290.92M
$249.16M
N/A
In Q1 FY2026 (ended March 31, 2026), OmniAb reported revenue of $14.4 million, a 247% increase year-over-year. Net loss narrowed to $7.7 million from $18.2 million in the prior year, while operating loss improved to $7.8 million. Diluted EPS was -$0.06, compared to -$0.17 in Q1 FY2025. Cash and cash equivalents stood at $29.0 million, with total equity of $262.6 million.
Estimates and expected reporting dates may change.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.
The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and target-binding proteins for partners' drug development efforts.
Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences.
Its portfolio also includes OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications, OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets, OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold, and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities.
It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. Founded in 2012, OmniAb is headquartered in Emeryville, California.
Quarterly report
Filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with unaudited financial statements and management's discussion of results.
10-Q
2026-10-30
SEC
Earnings results
Furnished a press release with its latest financial results (Item 2.02).
8-K ยท 2.02,9.01
2026-10-30
SEC
Quarterly report
OmniAb filed its quarterly report (10-Q) for Q2 FY2026 ended June 30, 2026, reporting revenue of $13.4 million and a net loss of $5.9 million.
10-Q
2026-08-06
SEC
Earnings results
On August 6, 2026, OmniAb filed an 8-K announcing earnings results (Items 2.02, 9.01).
8-K ยท 2.02,9.01
2026-08-06
SEC
Officer / director change
On July 13, 2026, OmniAb filed an 8-K regarding an officer or director change (Item 5.02).
8-K ยท 5.02
2026-07-13
SEC
Shareholder vote
On June 17, 2026, OmniAb filed an 8-K reporting results of a shareholder vote (Item 5.07).
8-K ยท 5.07
2026-06-18
SEC
Quarterly report
On May 7, 2026, OmniAb filed its quarterly report (10-Q) for Q1 FY2026 ended March 31, 2026.
10-Q
2026-05-07
SEC
Earnings results
On May 7, 2026, OmniAb filed an 8-K announcing earnings results for Q1 FY2026 (Items 2.02, 9.01).
8-K ยท 2.02,9.01
2026-05-07
SEC
Proxy statement
On April 29, 2026, OmniAb filed its proxy statement (DEF 14A) for the 2026 annual meeting.
DEF 14A
2026-04-29
SEC
Annual report
On March 4, 2026, OmniAb filed its annual report (10-K) for the fiscal year ended December 31, 2025.
10-K
2026-03-04
SEC
OmniAb, Inc. is a biotechnology company that licenses its discovery research technology to pharmaceutical and biotech companies, as well as academic institutions, to enable the discovery of therapeutics. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and target-binding proteins for partners' drug development efforts. Its OmniAb platform uses Biological Intelligence to power the immune systems of proprietary and engineered transgenic animals, generating optimized antibody candidates for human therapeutics. Key animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which are genetically modified to produce antibodies with human sequences. Additionally, OmniAb offers OmniFlic and OmniClic for bispecific antibody discovery, OmniTaur for cow-inspired antibodies, OmnidAb for single-domain antibodies, and OmniDeep, a suite of AI and machine learning tools for therapeutic discovery and optimization.
OmniAb, Inc. is listed on the NasdaqGM exchange under the ticker symbol OABI. The company's stock is traded in United States Dollars (USD). As a publicly traded company on a major US exchange, its financial reporting and share pricing are denominated in USD, which is the standard currency for companies listed in the United States.
OmniAb, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing and licensing advanced antibody discovery technologies for therapeutic development. The company's work involves genetic engineering of animals to produce human-like antibodies, which are then used by partners to create drugs for various diseases. This places OmniAb at the intersection of biotechnology and drug discovery, serving the broader healthcare ecosystem.
OmniAb, Inc. is headquartered in Emeryville, California, United States. The company serves clients in the United States, Europe, Japan, China, and Canada. Its technology is licensed to pharmaceutical and biotech companies, as well as academic institutions, across these regions. OmniAb's global reach allows it to collaborate with partners worldwide in the discovery of antibody-based therapeutics, leveraging its proprietary platforms to address a wide range of disease targets.
OmniAb, Inc. generates revenue by licensing its discovery research technology to pharmaceutical and biotech companies, as well as academic institutions. The company's business model is based on providing access to its OmniAb platform, which includes a suite of transgenic animal technologies (such as OmniRat, OmniChicken, and OmniMouse) and in silico tools like OmniDeep. Partners use these technologies to discover and optimize antibody candidates for human therapeutics. Additionally, OmniAb has an agreement with mAbsolve Ltd. to incorporate its Fc-silencing platform technology into antibodies generated using OmniAb's discovery platform, which may also contribute to revenue through licensing or collaboration fees.
Yahoo ยท Nov 1, 2026
OmniAb (OABI) Q3 Results Keep Cash Progress In Focus
SeekingAlpha ยท Oct 31, 2026
OmniAb: A Self-Funding Option Book On 433 Partner Programs
Yahoo ยท Oct 30, 2026
OmniAb, Inc. Q3 2026 Earnings Call Summary
Yahoo ยท Oct 30, 2026
OmniAb (OABI) Q3 2026 Earnings Call Transcript
Benzinga ยท Oct 30, 2026
OmniAb Q3 2026 Earnings Call Transcript
Yahoo ยท Oct 30, 2026
OmniAb Q3 Earnings Call Highlights
Americas
Europe
Asia